MediPaper Hong Kong

Medical Communications &Health News

Therapeutic Areas

IMMUNO-ONCOLOGY ARTICLES

innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

15th October 2018/by News Feed

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

SUZHOU, China, Oct. 14, 2018 /PRNewswire/ -- The combination therapy of novel programmed death 1 (PD-1) antibody IBI308 (sintilimab, Innovent Biologics) with biosimilar bevacizumab antibody IBI305 (Innovent Biologics) has received the investigational new drug (IND) application for clinical development approval by the National Medical Products Administration (NMPA, formerly known as CFDA) in China.

IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

11th October 2018/by News Feed

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

9th October 2018/by Stijn van den Borne, MSc

U.S. FDA approved immune-checkpoint inhibitors updated 08-Oct-2018

Pembrolizumab plus chemotherapy effective in squamous NSCLC

8th October 2018/by News Feed

Pembrolizumab plus chemotherapy effective in squamous NSCLC

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

7th October 2018/by News Feed

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

5th October 2018/by News Feed

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

2nd October 2018/by News Feed

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

ONCOLOGY ARTICLES

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

5th October 2018/by News Feed

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

Brigatinib (Alunbrig®, Ariad) significantly prolongs the progression-free survival (PFS) in anaplastic lymphoma kinase (ALK) inhibitor-naïve patients with ALK-rearranged non-small cell lung cancer (NSCLC) when compared to crizotinib, as resulted from the ALTA-1L study.

Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

25th September 2018/by News Feed

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

24th September 2018/by Stijn van den Borne, MSc

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

Early breast cancer treatment in China remains conservative

23rd September 2018/by News Feed

Early breast cancer treatment in China remains conservative

immuno-oncology I-O treatment for the irAE Rash

©MediPaper Medical Communications Ltd

21st September 2018/by Stijn van den Borne, MSc

ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash

Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

19th September 2018/by Stijn van den Borne, MSc

Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

Camrelizumab anti-PD-1 with or without Chemotherapy for NPC

18th September 2018/by News Feed

Camrelizumab anti-PD-1 with or without chemotherapy for NPC

Therapeutic Areas

MEMBERS ONLY

irAE immune-related adverse events immune-mediated adverse events hepatitis pneumonitis rash diabetes_small

©invincible7 / 123RF Stock Photo

CONFERENCE HIGHLIGHTS

COMING SOON

ESMO-2018-ESMO18-pembrolizumab-nivolumab-durvalumab-atezolizumab-avelumab-ipilimumab-tremelimumab-osimertinib-cabozantinib-lenvatinib-lorlatinib

©European Society for Medical Oncology

ASCO 2018 ASCO18 pembrolizumab nivolumab durvalumab atezolizumab avelumab ipilimumab tremelimumab olaparib rucaparib niraparib PARP palbociclib ribociclib abemaciclib CDK46 osimertinib cabozantinib lenvatinib lorlatinib

©American Society for Clinical Oncology (ASCO)

aacr2018 american association for cancer research annual meeting 2018 AACR 2018 AACR annual meeting 2018

©American Association for Cancer Research

CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology

©Chinese Society for Anesthesiology

© European Society for Medical Oncology

ASCO 2016 annual meeting

©American Society of Clinical Oncology

ONCOLOGY ARTICLES (Cont’d)

Adrian TSE HKIOC irAE pneumonitis lung immunotherapy-induced pneumonitis I-O Immuno-Oncology cannonball metastases cancer

©MediPaper Medical Communications Ltd

14th September 2018/by Stijn van den Borne, MSc

I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis

Learn how to treat immune-related adverse events (irAE). Dr Adrian Tse (Gleneagles Hospital) discusses a case report a patient with the irAE pneumonitis.

Quizartinib Receives Orphan Drug Designation for FLT3-Mutated AML in Japan

12th September 2018/by News Feed

Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

Lung Cancer Capmatinib plus gefitinib promising in MET-dysregulated NSCLC MediPaper Medical Communications Medical Writer Hong Kong 醫學寫作醫學作家香港

© Eraxion / 123RF Stock Photo

11th September 2018/by News Feed

Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

CAR-TCR Summit 2018 Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

© Royaltystockphoto / 123RF Stock Photo

9th September 2018/by News Feed

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

DRIVER connects cancer patients in China and the United States to the best care

© Kentoh / 123RF Stock Photo

7th September 2018/by News Feed

DRIVER connects cancer patients in China and the United States to the best care

Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

31st August 2018/by News Feed

Plasma TMB predicts response to atezolizumab in NSCLC patients

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

© luchschen / 123RF Stock Photo

22nd August 2018/by News Feed

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

Talazoparib in advanced breast cancer patients with a germline BRCA1:2 mutation

19th August 2018/by News Feed

Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

CheckMate 032 Nivolumab ipilimumab metastatic esophagogastric cancer

18th August 2018/by News Feed

CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

©Alex011973 / 123RF Stock Photo

13th August 2018/by News Feed

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

TAVR transcatheter aortic valve replacement with Portico valve reduces severe aortic stenosis in real-world study PORTICO-1

28th September 2018/by News Feed

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

Transcatheter aortic valve replacement (TAVR) with the Portico® valve (Abbott) was found to be safe and associated with low rates of stroke, death or paravalvular leakage at one-year follow-up, according to the real-world PORTICO I study in patients with symptomatic, severe aortic stenosis.

TAVR vs SAVR - Transcatheter- vs surgical aortic valve replacement in high-risk patients 5-years survival

28th September 2018/by News Feed

Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

19th September 2018/by News Feed

Anti-coagulation: impact on long-term mortality and early valve dysfunction

29th August 2018/by News Feed

Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety

29th August 2018/by News Feed

Febuxostat prevents CV events in hyperuricaemia patients

FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information. July 31, 2018.

1st August 2018/by News Feed

Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients

30th July 2018/by News Feed

Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety

Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

6th April 2018/by Stijn van den Borne, MSc

I-O in Special Populations: Diabetes and Concomitant Steroids

Latest global trends of health measure and impact on survival rate

16th August 2017/by Stijn van den Borne, MSc

Latest global trends of health measure and impact on survival rate

scientific symposium highlights optimisation of aerosol delivery in patients with poor asthma control aerosol delivery asthma

18th July 2017/by Stijn van den Borne, MSc

Optimisation of aerosol delivery in patients with poor asthma control

3rd October 2018/by News Feed

PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

On September 28, 2018, the FDA approved programmed death 1 (PD-1) immune-checkpoint inhibitor cemiplimab-rwlc (Libtayo®, Regeneron) for use in patients with metastatic cutaneous squamous cell carcinoma (CSCC) and patients with locally advanced CSCC unamenable for curative surgery or curative radiation.

28th September 2018/by News Feed

Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC

©United States Food and Drug Agency US FDA

25th September 2018/by News Feed

Duvelisib FDA approved for adult patients with R/R CLL or SLL

©United States Food and Drug Agency US FDA

25th September 2018/by News Feed

Duvelisib FDA approved for adult patients with R/R follicular lymphoma

©United States Food and Drug Agency US FDA

14th September 2018/by News Feed

Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia

©United States Food and Drug Agency US FDA

12th September 2018/by News Feed

Venetoclax FDA label updated to include Minimal Residual Disease negativity data

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

21st August 2018/by News Feed

Pembrolizumab and atezolizumab USPIs updated by FDA

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

21st August 2018/by News Feed

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

21st August 2018/by News Feed

Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

18th August 2018/by News Feed

Lenvatinib FDA approved for 1st-line treatment of HCC

© Copyright - MediPaper Medical Communications - Medical Communications & Health News